Montevideo, Uruguay, November 1, 2017 – GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that it has launched ABRAXANE® / ABRAXUS® (nab-paclitaxel) in Brazil and Mexico.
Early this year, GBT had received exclusive rights from Celgene Corporation to promote, market, sell and distribute the products in the before mentioned territories.
During the month of October, several launch events were organized impacting an approximate 500 oncologists specialized in the treatment of pancreatic and breast cancers. During these scientific meetings, local and international experts discussed on the unmet medical needs of these conditions, evidence based-treatment guidelines and specially, on the profile and role of novel nab-paclitaxel in the medical practice.
“We are very honored to bring new hope to thousands of pancreatic cancer patients in Brazil and Mexico, a devastating disease with such high unmet medical needs” said Daniel Flores, Sr. Scientific Advisor GBT-Grupo Biotoscana.
About GBT-Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical and LKM. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.
About ABRAXANE® / ABRAXUS®
In Brazil, ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is indicated for the first-line treatment of metastatic adenocarcinoma of the pancreas in combination with gemcitabine.
In Mexico, ABRAXUS® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease. Prior therapy should have included an anthracycline unless clinically contraindicated. ABRAXUS® is also indicated for the first-line treatment of metastatic adenocarcinoma of the pancreas in combination with gemcitabine.